Anemia en pacientes mayores de 18 años con diagnóstico de insuficiencia renal crónica sin tratamiento con eritropoyetina, hierro u ácido fólico

Abstract

Abstract: Introduction: Anemia associated with CRF continues tobe a health problem worldwide, due to the comorbidities it presents, the high costs it demands, the levels of mortality that it represents if treatment is received or not, and the consequences it presents. Objective: To compare the prevalence of anemia in patients over 18 years of age with a diagnosis of CRF who do not receive treatment and those who do receive treatment. Methods: articles were obtained through Google Scholar, Clinical Key, Pubmed, Elsevier, Cochrane, etc. From which the most appropriateinformation was extracted to develop this research. Results: the prevalence of anemia associated with CRF is higher from stage 3, but it can appear at any stage. Treatment with EPO, iron and folic acid improves anemia, but does not decrease the progression of kidney damage and those that are not treated have higher comorbidities and increased mortality rate. Conclusions: Patients with CKD present with anemia that reduces the quality of life of the patient. Not receiving treatment has a high prevalence and mortality rate in patients.